1. Home
  2. IPO
  • Accretion Pharmaceuticals Ltd IPO
Accretion Pharmaceuticals logo

Accretion Pharmaceuticals IPO

  • Status: Closed
  • RHP:
  • ₹ 115,200 / 1200 shares

    Minimum Investment

IPO Listing Details

  • Listing Date

    21 May 2025

  • Listing Price

    ₹ 79.00

  • Listing Change

    -

  • Last Traded Price

    ₹ 78.80

IPO Details

  • Open Date

    14 May 2025

  • Close Date

    16 May 2025

  • Listing Date

    21 May 2025

  • IPO Price Range

    ₹ 96 to ₹ 101

  • IPO Size

    ₹ 29.75 Cr

  • Listing Exchange

    NSE SME

With just a few clicks, invest in IPOs!

+91
Resend OTP

By proceeding, you agree to all T&C*

hero_form
Timeline Subscription Status Financials SWOT FAQ Contacts

IPO Timeline

Accretion Pharmaceuticals IPO Subscription Status

Last Updated: 22 May 2025 11:39 AM by 5Paisa

Accretion Pharmaceuticals Limited is launching its IPO. Based in Sanand, Gujarat, the company manufactures and markets tablets, capsules, oral liquids, ointments, creams, gels, powders, and more. It also offers contract manufacturing services and holds ISO 9001:2015, 14001:2015, and 22000:2005 certifications. With a strong focus on quality, Accretion has expanded internationally, establishing its presence in over 20 countries across Africa, Southeast Asia, and the Middle East.

Established in: 2012
Managing Director: Mr. Vivek Patel

Peers

Sakar Healthcare Limited
Lincoln Pharmaceuticals Limited
Sotac Pharmaceuticals Limited
 

Objectives

1. Purchase of machinery and equipment
2. Capex to upgrade existing manufacturing facilities
3. Funding working capital requirements
4. Repayment/ prepayment of borrowings
5. General corporate purposes

Accretion Pharmaceuticals IPO Size

Types Size
Total IPO Size ₹29.75 Cr.
Offer For Sale -
Fresh Issue ₹29.75 Cr.

 Accretion Pharmaceuticals IPO Lot Size

Application Lots Shares Amount
Retail (Min) 1 1200 115,200
Retail (Max) 1 1200 115,200
HNI (Min) 2 2400 230,400

Accretion Pharmaceuticals IPO Reservation

Investors Category Subscription (times) Shares Offered Shares bid for Total Amount (Cr.)*
QIB 12.14 1,41,600 17,19,600 17.37
NII (HNI) 4.28 12,22,800 52,36,800 52.89
Retail 10.54 12,22,800 1,28,85,600 130.14
Total** 7.67 25,87,200 1,98,42,000 200.40

 

*The "Shares Offered" and "Total Amount" are calculated using the upper limit of the issue price range.
**Shares allocated to anchor investors (or market makers) are excluded from the total number of shares offered.

Profit and Loss

Balance Sheet

Particulars (in Rs. Crores) FY22 FY23 FY24
Revenue 22.58 29.53 33.94
EBITDA 1.93 2.14 7.76
PAT 0.08 0.10 3.88
Particulars (in Rs. Crores) FY22 FY23 FY24
Total Assets 17.74 20.58 27.05
Share Capital 3.08 3.84 4.00
Total Borrowings 7.61 8.47 13.48
Particulars (in Rs. Crores) FY22 FY23 FY24
Net Cash Generated From / (used in) operating activities 2.15 0.32 -1.33
Net Cash Generated From / (used in) investing activities -0.26 -1.10 -0.11
Net Cash Generated From / (used in) financing activities -1.58 0.44 1.49
Net Increase (Decrease) In Cash And Cash Equivalents 0.31 -0.34 0.06


Strengths

1. Experienced promoters with deep industry knowledge.
2. Strong client and supplier relationships.
3. Focused on high-quality pharmaceutical products.
4. Certified for quality and environmental management systems.


 

Weaknesses

1. Operations depend on a single manufacturing facility.
2. Exposed to ongoing legal and regulatory proceedings.
3. High compliance burden in international markets.
4. Limited diversification in manufacturing locations.
 

Opportunities

1. Expanding presence in emerging global markets.
2. Rising demand for contract manufacturing services.
3. Potential to introduce new healthcare products.
4. Increasing global focus on affordable generics.
 

Threats

1. Geopolitical risks in export markets.
2. Non-compliance could lead to legal or regulatory action.
3. Currency volatility impacts export earnings.
4. Regional disruptions may affect manufacturing continuity.


 

1. Strong financial growth with PAT rising to ₹3.88 Cr in FY24 from ₹0.10 Cr in FY23.
2. Global presence across 20+ countries and holds ISO 9001, 14001, and 22000 certifications.
3. Operates in a growing pharma industry expected to reach $130 billion by 2030.
4. IPO funds to support facility upgrades, machinery purchase, and working capital needs.
 

1. India ranks third globally in pharmaceutical production by volume with over 10,500 manufacturing units.
2. The country supplies 40% of U.S. generics, 25% of U.K. medicines, and 50% of global vaccine demand.
3. The sector is shifting toward innovative therapies, biosimilars, and biologics to drive future growth.
4. Indian pharmaceutical market is projected to reach $130 billion by 2030 amid rising global demand.
 

Will You Apply for Accretion Pharmaceuticals IPO?

Yes No Maybe

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91
Resend OTP

By proceeding, you agree to all T&C*

footer_form

FAQs

Accretion Pharmaceuticals IPO opens from 14 May 2025 to 16 May 2025.

The size of Accretion Pharmaceuticals IPO is ₹29.75 Cr.

The price of Accretion Pharmaceuticals IPO is fixed at ₹96 to ₹101 per share. 

To apply for Accretion Pharmaceuticals IPO, follow the steps given below:

● Login to your 5paisa account and select the issue in the current IPO section    
● Enter the number of lots and the price at which you wish to apply for the Accretion Pharmaceuticals  IPO.    
● Enter your UPI ID and click on submit. With this, your bid will be placed with the exchange.    

You will receive a mandate notification to block funds in your UPI app.
 

The minimum lot size of Accretion Pharmaceuticals IPO is 1,200 shares and the investment required is ₹115,200.

The share allotment date of Accretion Pharmaceuticals IPO is 19 May 2025

The Accretion Pharmaceuticals IPO will likely be listed on 21 May 2025.

Jawa Capital Services Private Limited is the book running lead manager for Accretion Pharmaceuticals IPO.
 

Accretion Pharmaceuticals plans to utilise the raised capital from the IPO for:

1. Purchase of machinery and equipment
2. Capex to upgrade existing manufacturing facilities
3. Funding working capital requirements
4. Repayment/ prepayment of borrowings
5. General corporate purposes